Royalty Report: Drugs, Disease, Delivery – Collection: 369293

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 18

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18

Primary Industries

  • Drugs
  • Disease
  • Delivery
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Cannabis
  • Gastrointestinal
  • Drug Discovery
  • Pain
  • Diabetes Treatment

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369293

License Grant
Licensor hereby grants to Licensee an exclusive (even as against Licensor and its Affiliates), nontransferable (except with respect to the assignment provision in Agreement) limited license during the Term under the Licensed Patents, solely to make, have made (pursuant to Agreement), use, sell, offer for sale and import the Licensed Products in the Territory in and for the Field. (No license, exclusive or nonexclusive, is granted hereunder under the Licensed Patents, except to so make, have made, use, sell, offer for sale and import the Licensed Products in the Territory in and for the Field.)
License Property
Patents
5,874,418 – Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
6,046,177 – Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
6,133,248 – Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof

Licensed Product means (a) a Compound combined with or formulated using Captisol for ultimate use in humans in a dosage form/formulation, or (b) a pharmaceutical composition that includes a Compound and that is developed with the assistance of or incorporates any then-confidential component of the Captisol Data Package.

Compound means the proprietary Licensee isoflavone-based drug compound known as ME-143 (also known as NV-143) or the proprietary Licensee mitochondrial inhibitor drug compound known as ME-344, or any derivative, homolog, or analog of ME-143 or ME-344 or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing.

Captisol Related Compound means Captisol or any derivative, homolog analog of Captisol or any isomer, salt, hydrate, solvate, amide, ester, metabolite or product of any of the foregoing, including without limitation sulfobutylether g(gamma) cyclodextrin sodium salt.

Licensed Product Family means one or more Licensed Products which are based on the same Compound(s) (or any isomers, salts, hydrates, solvates, amides, esters, metabolites, or prodrugs of the foregoing), irrespective of whether such Licensed Products contain different dosage forms, proportions or formulations of such Compound(s), utilize different inactive ingredients and/or are marketed for different indications. Notwithstanding the foregoing, a Licensed Product based on a Compound shall be deemed to be in a distinct Licensed Product Family from a Licensed Product based on the combination of the same relevant Compound with any other active pharmaceutical ingredient. As such, if Licensee develops one Licensed Product with ME-344 as the sole active ingredient with Captisol and also develops another Licensed Product with ME-344 in combination with another active ingredient with Captisol, then two distinct sets of milestone payments shall be potentially due under this Agreement, one for each of such two distinct Licensed Products.

Field of Use
Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

Captisol is  for use with the Licensee’s isoflavone-based drug compounds.

ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause cell death in multiple human tumor cell lines, including ovarian cancer stem cells, by interfering with mitochondrial energy generation.

Field means the entire field of prevention, diagnosis and treatment of all human and animal diseases and disorders with the exceptions of (i) ocular treatment of any disease or condition with a formulation including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration.

IPSCIO Record ID: 194661

License Grant
Licensor grants an exclusive right to use a specific compound.
License Property
The licensors compound is Captisol®.

Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

Field of Use
Licensee is using the compound in its development and commercialization of a Captisol®-enabled version of a specified compound.

IPSCIO Record ID: 383555

License Grant
For the Licensed Patents, Licensor grants an exclusive, nontransferable license during the Term under the Licensed Patents, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

For the Know-How License, Licensor grants an exclusive, nontransferable license during the Term under Licensors rights in and to the Captisol Data Package and Product Know-How, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

License Property
Licensor is engaged in the business of developing and commercializing novel drug delivery technologies designed to enhance the solubility and effectiveness of existing and development-stage drugs.

Licensor is the exclusive worldwide licensee of Captisol®.

Licensor has developed or obtained certain rights related to the Compound.

Captisol means Captisol®, also known scientifically as sulfobutylether B(beta) cyclodextrin, sodium salt.

Captisol Data Package means
—  all toxicology/safety and other relevant scientific safety data owned, licensed or developed by Licensor and its Affiliates; and,
—  all toxicology/safety and other relevant scientific safety data owned, licensed or developed by the licensees or sublicensees of Licensor or its Affiliates or other third parties, to the extent permitted in the applicable license or other agreements between Licensor and/or its Affiliates and such licensees, sub licensees or other third parties), in each case on Captisol alone, and not in conjunction with a product formulation.

Compound means that certain pharmaceutical compound with the chemical name clopidogrel, including all of its isomers, salt, ester, and polymorphic forms.

Licensed Patents means, collectively, the Captisol Patents and the Licensed Product Patents.

Licensed Product means a pharmaceutical composition comprising the Compound in an injectible dosage form/formulation suitable for human use Covered by the Licensed Patents or Product Know-How or Captisol Data Package, including without limitation, an injectible pharmaceutical composition comprising the Compound and Captisol.

Field of Use
The Field means all indications, including without limitation, all dosages, formulations, uses, and routes of administration for the Licensed Product.  Captisol® is a patented drug formulation system designed to enhance the solubility and stability of drugs.  Captisol® has been used quite successfully in solid formulations to assist in solubilization, dissolution and improved absorption.

IPSCIO Record ID: 248288

License Grant
Licensor hereby grants to Company, an exclusive, nontransferable license in the Field during the Term under the Licensed Patents, solely to make, use, sell, offer for sale and import the Licensed Product in the Territory. Company may not make, use, sell, offer for sale, or import the Licensed Product for any other purposes. Company may not sublicense the Licensed Patents, except as expressly set forth in the Agreement.

Licensor hereby grants to Company a non-exclusive, nontransferable license during the Term under Licensor’s right in and to the Captisol Data Package, solely to make, use, sell, offer for sale and import the Licensed Product in the Territory in the Field. Company may not sublicense its rights to the Captisol Data Package.

License Property
Licensed Product means the Compound combined with or formulated using Captisol covered by the Licensed Patents in all dosage forms/formulations for ultimate use in humans. For clarity, the Licensed Product shall not include any product which is a combination product incorporating the Compound with any other active pharmaceutical ingredient.

Captisol means Captisol , also known scientifically as sulfobutylether ~(beta) cyclodextrin, sodium salt.

Compound means that certain pharmaceutical compound known as NS-2 with the chemical name 2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol, owned by or licensed to Company and developed and manufactured by or on behalf of Company.

Licensed Patents
5,134,127 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
5,376,645 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
7,629,331 – Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof  
7,635,773 – Sulfoalkyl ether cyclodextrin compositions

Field of Use
Field means any ocular treatment for retinal degeneration excluding (i) any products by any company with which Licensor has a pre-existing license agreement in which retinal degeneration has not been excluded as a licensed field, (ii) monoclonal antibodies, or (iii) any ocular formulation of an Androgen Hormone ( e.g. a testosterone) which includes sulfobutyl ether beta-cyclodextrin.

IPSCIO Record ID: 203259

License Grant
Licensor grants an exclusive, nontransferable license during the Term under the Licensed Patents, solely to develop, make, have made, use, market, distribute, sell, offer for sale and import the Product in the Field in the Territory.
License Property
The Product is the Compound combined with or formulated using CAPTISOL in a parenteral dosage form/formulation.  CAPTISOL® is also known scientifically as sulfobutylether b(beta) cyclodextrin, sodium salt.

Captisol may be applied in drug delivery in many ways. The primary applications are to enhance solubility and stability. Solubility increases of tens of thousand are possible, and when combined with pH and selected salts, solubility increases of hundreds of thousands have been observed.

Field of Use
The Field means the treatment of any and all diseases and conditions in humans, except for the treatment or prophylaxis of fungal infections; or as a topical ocular treatment of dry eye.

IPSCIO Record ID: 383554

License Grant
For the Licensed Patents, Licensor grants an exclusive, nontransferable license during the Term under the Licensed Patents, solely to make, use, sell, offer for sale and import the Licensed Product in the Territory in the Field.

Licensor grants a non-exclusive, nontransferable license under Licensors right in and to the Captisol Data Package, solely to make, use, sell, offer for sale and import the Licensed Product in the Territory in the Field.

License Property
Licensor is developing and commercializing novel drug delivery technologies designed to enhance the solubility and effectiveness of existing and development-stage drugs, including without limitation Captisol®, a patented drug formulation system designed to enhance the solubility and stability of drugs.

Captisol means Captisol®, also known scientifically as sulfobutylether B(beta) cyclodextrin, sodium salt.

Captisol Data Package means all toxicology/safety and other relevant scientific safety data owned, licensed or developed by Licensor and its Affiliates; and all toxicology/safety and other relevant scientific data owned, licensed or developed by the licensees or sublicensees of Licensor or its Affiliates or other third parties, to the extent permitted in the applicable license or other agreements between Licensor and/or its Affiliates and such licensees, sublicensees or other third parties, in each case on Captisol alone, and not in conjunction with a product formulation.

Field of Use
Captisol is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  Captisol® has been used quite successfully in solid formulations to assist in solubilization, dissolution and improved absorption.

IPSCIO Record ID: 266776

License Grant
For the Licensed Patents,  Licensor grants an exclusive, nontransferable license during the Term under the Licensed Patents, solely to develop, make, have made, use, market, distribute, import, offer to sell and sell the Licensed Product in the Territory.

For the CAPTISOL Data Package, Licensor grants a non-exclusive, nontransferable license during the Term under Licensors right in and to the CAPTISOL Data Package, solely to develop, make, have made, use, market, distribute, import, offer to sell and sell the Licensed Product in the Territory.

License Property
Licensor is engaged in the business of developing and commercializing novel drug delivery technologies designed to enhance the solubility and effectiveness of existing and development-stage drugs.

Licensor is the exclusive worldwide licensee of CAPTISOL®, a patented drug formulation system.

CAPTISOL means the drug formulation technology marketed by Licensor as CAPTISOL®, also known scientifically as sulfobutylether ~(beta) cyclodextrin, sodium salt.

The CAPTISOL Data Package means all toxicology/safety and other relevant scientific safety data owned, licensed or developed by Licensor and its Affiliates; all toxicology/safety and other relevant scientific data owned, licensed or developed by the licensees or sublicensees of Licensor or its Affiliates or other third parties on CAPTISOL alone, and not in conjunction with a product formulation; and all CMC and manufacturing process data relating to the preparation of CAPTISOL, in each case to the extent necessary or useful for the formulation of the Licensed Product.

Licensed Product means the Compound combined with or formulated using CAPTISOL in an injectable dosage form/formulation for ultimate use in humans.

Captisol® is a modified cyclodextrin that can form ionic and inclusion complexes with many types of drugs. Complexation can significantly increase the solubility and often times, the physico chemical stability of the drug. Complexation has also been used to improve dissolution and bioavailability, reduce volatility, allow incorporation of liquids into solid formulations, and reduce unpleasant side effects such as taste and irritation caused by drug contact with tissues, e.g. extravasation at injection sites and GI irritation.

Field of Use
The technology is designed to enhance the solubility and stability of drugs.  patented Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs.

Captisol® enabling technology is for the development of an injectable formulation of zileuton (ZYFLO®).
ZYFLO CR and ZYFLO are indicated for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. The injectable formulation of zileuton is being developed for use in emergency room or urgent care settings for patients experiencing acute exacerbations of asthma.

IPSCIO Record ID: 332232

License Grant
Licensed Patents. Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under the Licensed Patents, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

Know-How License Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under Licensor’s rights in and to the Captisol Data Package and Product Know-How, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

License Property
Captisol means Captisol®, also known scientifically as sulfobutylether ß(beta) cyclodextrin, sodium salt, including all of its optical isomers, and salt, ester, and polymorphic forms.

US Serial Number 12/790,724

Compound means that certain pharmaceutical compound known as melphalan, including all of its optical isomers, and salt, ester, and polymorphic forms.

US Patent #5,376,645 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US Patent #7,629,331 – Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US Patent #7,635,773 – Sulfoalkyl ether cyclodextrin compositions

Field of Use
The Captisol-enabled melphalan product candidate is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 45261

License Grant
Licensor grants to Company an exclusive, nontransferable license during the Term under the Licensed Intellectual Property, solely to develop, make, have made, use, sell, market, offer for sale, import and otherwise commercially exploit the Licensed Products.
License Property
The licensed property is all trade secret and Know-How rights which relate to the preparation, combination and/or formulation of a Compound with Captisol, including proprietary and confidential information contained in the Captisol Data Package.  The Licensed Patents are all worldwide patents and patent applications which cover Captisol or any Licensed Product  owned by or licensed to Licensor with the right to sublicense.  Captisol means sulfobutylether ß(beta) cyclodextrin, sodium salt.  Captisol® is a patented drug formulation system designed to enhance the solubility and stability of drugs.
Field of Use
The field is the entire field of prevention, diagnosis and treatment of all human and animal diseases and disorders with certain exceptions.

IPSCIO Record ID: 925

License Grant
The Licensor hereby grants the Licensee an exclusive, non-transferable License for the duration of the Evaluation Period under the Licensed Patents and know-how, solely for research and development of drug products combining or formulating one or more of the Compounds, alone or as part of the Combination, with Captisol for the field of use consisting of all therapeutic uses in humans. The Licensee shall have the right to grant sub-licenses to any Third Party.
License Property
The Licensor is the exclusive supplier of Captisol®.  Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to solubilize and stabilize active drug ingredients.
Field of Use
Field means all therapeutic uses in humans.

IPSCIO Record ID: 280946

License Grant
Licensor agrees to grant and hereby grants to Licensee the following licenses, with the right to sublicense, under the Licensor Patents and Licensor Know-How (i) an exclusive (even as to Licensor) license in the Territory to develop, import, use, sell and offer for sale Licensed Products for Licensed Indications in the Field; and (ii) a non-exclusive worldwide license to develop, import, make and have made Licensed Products solely for sale in the Territory in the Field, which license shall be exclusive, even as to Licensor, regarding import and sale of Licensed Products in the Field in the Territory.
License Property
Licensor Patents means (i) the patents and patent applications listed, including those in-licensed by Licensor in the Missouri Agreement; and (ii) all additional patent applications and patents owned or Controlled by Licensor in the Territory which are directed to pharmaceutical products containing one or more PPIs with one or more buffering agents and which pharmaceutical products provide for immediate release of the PPI included in such product.
5,840,737 – Omeprazole solution and method for using same
6,489,346 – Substituted benzimidazole dosage forms and method of using same
6,780,882 – Substituted benzimidazole dosage forms and method of using same

Product(s) means pharmaceutical compositions containing any one or more PPIs in combination with one or more buffering agents, which pharmaceutical compositions provide for immediate release of the PPI included in such product, including (i) any prodrugs and metabolites, and all esters, salts, hydrates, solvates, polymorphs and isomers of any of the above, (ii) chemical analogs, and (iii) Formulations (including tablets, chewable tablets, capsules, caplets, liquid forms and powders for oral suspensions) of any of the above.

PPI means proton pump inhibitor.

Licensed Product(s) means any of the following OTC Products (i) Products containing a 20 mg dose of omeprazole and no other PPI, (ii) Products containing omeprazole (and no other PPI) at doses other than 20 mg, (iii) Combination Products that are approved.

OTC Product means all Formulations, dosages, package sizes and configurations and types of Products for which a prescription from a health care practitioner is not required in order to dispense, purchase or use such Product in the Territory.

The product is Zegerid® branded immediate-release omeprazole products for the over-the-counter (“OTC”).  Zegerid is a proton pump inhibitor (PPI), the strongest and most effective class of acid-reducing medication for treating frequent heartburn.

Field of Use
Field means all therapeutic uses and Indications in humans for which a physician’s prescription is not required. This may be used interchangeably with the phrase “OTC market”.
It can treat heartburn, a damaged esophagus, stomach ulcers, and gastroesophageal reflux disease (GERD).

IPSCIO Record ID: 183241

License Grant
The Licensor announced the signing of exclusive global license and supply agreements with the Licensee for three captisol enabled programs, one of which is Fosphenytoin.
License Property
Captisol is a modified cyclodextrin preparation, designed to optimize the solubility and stability of drugs.

Captisol-enabledâ„¢ Fosphenytoin is an IV and IM compound specifically formulated for patients at risk for or to control status epilepticus seizures occurring during or following neurosurgery or neurologic trauma.

Fosphenytoin (fosphenytoin sodium) is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is most commonly used in the acute treatment convulsive status epilepticus.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.  IM/IV CE Fosphenytoin is for patients with seizures.

Field of Use
This agreement is for the drug industry.

IPSCIO Record ID: 299247

License Grant
Licensor grants
—  an exclusive license, with right to sublicense through one or more tiers, under the Licensed Patent Rights to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Products in the Field.  
—  an exclusive license, with right to sublicense through one or more tiers, under the Know-How, to make, have made, use, have used, sell, have sold, offer  for sale, have offered for sale, import and have imported Products in the Field and a nonexclusive license to any other know-how existing on the Closing Date and provided to Licensee which is useful to develop or commercialize the Products in the Field.
License Property
Licensor has research regarding small-molecule immune response modifier compounds and other small molecule compounds, some of which act by stimulating basic immune cell receptors known as toll-like receptors  (TLRs) 7 and/or 8.

The Assigned Patent Rights and Licensed Patent Rights include any prodrug or any hydrate, solvate, conjugate, salt, ester, stereoisomer or polymorph of such compound or prodrug.

Field of Use
The Field means the diagnosis, treatment, mitigation, or prevention of any disease or condition in humans or animals, other than uses that are within the Excluded Fields. The Excluded Fields are
—  the treatment, topically or systemically, of diseases of the cervix or vaginal tract caused by human papilloma virus (HPV) infection, including cervical high risk·HPV infection and cervical dysplasia, and the treatment of cervical malignancy by topical application to the cervix, but not including systemic treatments of cervical malignancy;
—  any use of imiquimod, 848 (resiquimod}, 850 (sotirimod), and the alkyl ureas S-32913 and S-33005, including any acid, ester, salt, amide, prodrug, polymorph, enantiomer or isomer thereof, and any pharmaceutical product containing such compounds, in the Topical Field, which means the treatment, mitigation, or prevention of a disease or condition by topical application (e.g., dermatological, pulmonary or vaginal) of the drug to the skin or mucosa (e.g., bronchialand vaginal tissue) of a patient by, for example, but not limited to, gels, creams, ointments, foams, lotions, salves, roll-ons, powders, sprays, or inhalants, like aerosols such as for asthma and allergic rhinitis;
—  marketing the 3MIRM Compounds 852 (N-[4-(4-amino-2-ethyl-1Himidazo[4;5 c]quinoliri-1-yl)butyl]methanesulfonamide) and/or 854 (N-{2-[4-amino-2 ( ethoxymethyl)-1 H-imidazo[ 4, 5-c]quinolin-1-yl]-1 , 1-d imethylethyl}methanesulfonamide)  (including any acid, ester, salt, amide, pro-drug, polymorph, enantiomer or isomer thereof, and.any pharmaceutical product containing such compounds) for the indications of genital warts, common warts, basal cell carcinoma, actinic keratosis, tattoo removal, or photoaging; and
— any use of the 3M Compounds as a Vaccine Adjuvant.

IPSCIO Record ID: 344539

License Grant
For the Research License, The Canadian Licensor grants to the Licensee of Japan a co-exclusive, solely with respect to Licensor, right and license, under the Licensor Intellectual Property, to conduct Licensees responsibilities under the Research Program in the Field in the Territory during the Selection Period.

For the Development and Commercialization License, Licensor grants an exclusive, even as to Licensor, right and license, under the Licensor Intellectual Property, to Develop Selected Compounds into Licensed Products intended for use in the Field in the Territory, and make and have made, use, offer for sale, sell, have sold and import Selected Compounds and Licensed Products in the Field in the Territory.

For the Grant of Certain Jointly Developed Methyl Gene Collaboration Intellectual Property for use Outside the Field, Licensor grants a perpetual, irrevocable, non-exclusive right and license to use, solely outside the Field, Licensor Collaboration Intellectual Property that is Formulation Technology or Know-How that directly relates to the physicochemical property pharmacokinetics/pharmacodynamics relationship in ocular tissue, and is jointly developed, conceived or created by or on behalf of Licensor and/or its Affiliates, on the one hand, and by or on behalf of Licensee and/or its Affiliates, on the other hand.

License Property
The patents are titled
Inhibitors of VEOF Receptor and HOF Receptor;
Inhibitors of Protein Tyrosine Kinase Activity;
Kinase Inhibitors and Uses Thereof;
Processes and Intermediates for Preparing Fused;
Heterocyclic Kinase Inhibitors;
Inhibitors of Protein Tyrosine Kinase Activity;
Inhibitors of Kinase Activity.

A Compound is a molecule that is a small molecule that is a small molecule tyrosine kinase inhibitor as its main mechanism of action, and any salts, hydrates, solvates, polymorphs, free base, isomers, prodrugs, metabolites and/or liposomal or other formulations thereof or other compositions consisting of such molecule non-covalently bonded with other moieties, but excluding any derivative of such molecule in which the chemical structure of such molecule is altered.

Field of Use
Field means the prevention, treatment, control, mitigation or palliation in humans of diseases, disorders and other medical conditions caused by choroidal angiogenesis, including, without limitation, age-related macular degeneration, and diabetic retinopathy and retinal edema; in each case using local delivery of the active pharmaceutical agents to the eye.  For the avoidance of doubt, “local delivery” shall include, without limitation, topical, intravitreal, periorbital, intraocular and other local administration to the eye, the ocular and/or periocular tissues and spaces, including, without limitation, via delivery devices, but in any event, subject to Section 3.6, shall not include systemic delivery, including, without limitation, parenteral or sublingual delivery or delivery through a patch.  The Field shall expressly exclude the prevention, treatment, control, mitigation or palliation of any Indications other than above (e.g., treatment of cancer, including, without limitation, neoplasia and other pre-cancerous conditions and ocular cancer, is excluded).

IPSCIO Record ID: 253915

License Grant
Licensor grants the Licensee, of England, an exclusive license, with the right to grant sublicenses, under the Licensor Patents and Licensor Know-How to develop, use, make, have made, offer for sale, sell, import, market, distribute and promote the Compound and Products, in each case solely in the Field in the Territory.

Licensee shall have a non-exclusive license, with the right to grant sublicenses, to use the Licensor Trademarks solely for market research and other similar activities to determine whether Licensee will use the Licensor Trademarks or Licensee Trademarks in connection with the commercialization and promotion of the Product in the Field in the Territory.

License Property
Licensor has developed a Transported Prodrugâ„¢ of gabapentin for the treatment of restless legs syndrome (RLS) and the management of neuropathic pain (which includes post-herpetic neuralgia and diabetic peripheral neuropathy.

The Compound shall mean that certain compound, referred to internally at Licensor as XP13512, and all esters, hydrates, metabolites [(excluding gabapentin), polymorphs, prodrugs of gabapentin], salts, solvates, isomers and/or mixtures of isomers thereof.

The patents are for the Compound Family,  Analog Prodrug Sustained Release Oral Dosage Form Families, Crystalline Form Family, Convergent Synthesis Family, Alternative Synthesis Method Families,  Therapeutic Use to treat RLS Family, Therapeutic Use to treat Hot Flashes Family,  Therapeutic Use to treat Incontinence Family,  Therapeutic Use to treat Premature Ejaculation Family,  Therapeutic Use to treat Vulvodynia Family,  Therapeutic Use to treat Tinnitus Family,  and,  Topical Composition/Use to treat Local Pain Family.

XP13512 is a patented, new chemical entity that is designed to improve upon the clinical utility of gabapentin by taking advantage of high-capacity transport mechanisms in the gut to improve absorption.

Field of Use
XP13512 is currently in Phase III development for Restless Legs Syndrome (RLS) and in Phase II development for neuropathic pain.

Restless legs syndrome (RLS) is a condition that causes an uncontrollable urge to move your legs, usually because of an uncomfortable sensation. It typically happens in the evening or nighttime hours when you're sitting or lying down. Moving eases the unpleasant feeling temporarily.

IPSCIO Record ID: 239010

License Grant
The French Licensor grants an exclusive, even as to Licensor, license under Licensor Intellectual Property, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market, commercialize, distribute, sell or otherwise dispose of Compound and Product for all uses in the Territory.
License Property
The patents incllude Echinocanoine Fongicide and the chemical compound HMR 3270.

The Deoxymulundocandin nucleus standard K91 is not fully characterized yet.

Compound shall mean the chemical compound known under the International Nonproprietary name aminocandin and the code name HMR-3270, and any other compounds disclosed or covered or included in the Licensor Patent Assets or any compound that is part of the aminocandin family of compounds or any derivative, homolog, or analog of any of the foregoing, and any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing that exists and is owned or controlled by Licensor as of the Effective Date.

Nucleus shall mean deacylmulundocandin, the starting material for the manufacture of the Compound, obtained by biochemistry through a biosynthesis from an Aspergillus strain, the first step of which leads to deoxymulundocandin and the second step of which leads to deacylmulundocandin.

“Compound” shall mean the chemical compound known under the International Non-proprietary name aminocandin and the code name HMR-3270.

Field of Use
Aminocandin is an echinocandin, a new class of anti-fungal compounds in development for the treatment of a broad spectrum of systemic, invasive fungal infections.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.